Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Pushes Back Action Date For Nuvigil Label Expansion Due To New Data

This article was originally published in The Pink Sheet Daily

Executive Summary

Cephalon, which has positioned Nuvigil to replace Provigil as the latter sleep drugs faces patent expiry, hopes to add treatment of jet lag to label.

You may also be interested in...



Cephalon's Nuvigil Jet Lag Indication Grounded By Complete Response Letter

Wall Street analysts question the extent to which the FDA move is a setback, given the outlook for the company's wakefulness franchise.

Cephalon's Nuvigil Jet Lag Indication Grounded By Complete Response Letter

Wall Street analysts question the extent to which the FDA move is a setback, given the outlook for the company's wakefulness franchise.

An Easy Landing? Cephalon Scores Priority Review For Nuvigil In Jet Lag Disorder

Some, however, remain skeptical of the medicine's potential after the Provigil patent expires.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS068917

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel